Analyzing Windtree Therapeutics (NASDAQ:WINT) and Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYSGet Rating) and Windtree Therapeutics (NASDAQ:WINTGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Krystal Biotech and Windtree Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Krystal Biotech N/A -15.99% -14.73%
Windtree Therapeutics N/A -145.63% -84.17%

Analyst Recommendations

This is a breakdown of current recommendations for Krystal Biotech and Windtree Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech 0 0 6 0 3.00
Windtree Therapeutics 0 0 0 0 N/A

Krystal Biotech presently has a consensus price target of $98.60, suggesting a potential upside of 76.04%. Given Krystal Biotech’s higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Windtree Therapeutics.

Earnings & Valuation

This table compares Krystal Biotech and Windtree Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Krystal Biotech N/A N/A -$69.57 million ($4.37) -12.96
Windtree Therapeutics $200,000.00 59.70 -$67.64 million ($2.48) -0.16

Windtree Therapeutics has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Krystal Biotech has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Windtree Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.

Institutional and Insider Ownership

76.6% of Krystal Biotech shares are owned by institutional investors. Comparatively, 11.4% of Windtree Therapeutics shares are owned by institutional investors. 17.8% of Krystal Biotech shares are owned by company insiders. Comparatively, 16.7% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Krystal Biotech beats Windtree Therapeutics on 7 of the 10 factors compared between the two stocks.

Krystal Biotech Company Profile (Get Rating)

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Windtree Therapeutics Company Profile (Get Rating)

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.